Get the Stockscreener App
3.15
2.27%
0.07
After Hours:
3.16
0.01
+0.32%
Adc Therapeutics Sa stock is traded at $3.15, with a volume of 268.23K.
It is up +2.27% in the last 24 hours and up +8.62% over the past month.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.
See More
Previous Close:
$3.08
Open:
$3.08
24h Volume:
268.23K
Relative Volume:
0.47
Market Cap:
$297.80M
Revenue:
$69.56M
Net Income/Loss:
$-240.05M
P/E Ratio:
-1.3877
EPS:
-2.27
Net Cash Flow:
$-121.90M
1W Performance:
+2.27%
1M Performance:
+8.62%
6M Performance:
-29.84%
1Y Performance:
+251.17%
1-Day Range:
$3.02
$3.23
1-Week Range:
$2.90
$3.23
52-Week Range:
$0.3599
$6.04
Adc Therapeutics Sa Stock (ADCT) Company Profile
Name
Adc Therapeutics Sa
Sector
Industry
Phone
41 21 653 02 00
Address
BIOPOLE, EPALINGES
Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-10-23 | Upgrade | JP Morgan | Underweight → Neutral |
| Apr-24-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-06-22 | Initiated | CapitalOne | Overweight |
| Nov-09-22 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Aug-17-21 | Resumed | Jefferies | Buy |
| Aug-09-21 | Initiated | RBC Capital Mkts | Outperform |
| Jun-15-21 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-03-20 | Initiated | Stifel | Hold |
| Oct-29-20 | Initiated | H.C. Wainwright | Buy |
| Jun-09-20 | Initiated | BofA/Merrill | Buy |
| Jun-09-20 | Initiated | Cowen | Outperform |
View All
Adc Therapeutics Sa Stock (ADCT) Latest News
Rhumbline Advisers Purchases Shares of 85,977 ADC Therapeutics SA (NYSE:ADCT) - Defense World
Adc Therapeutics (ADCT) Price Target Increased by 9.79% to 8.77 - MSN
Wall Street SWOT: ADC Therapeutics stock faces challenges amid potential growth - Investing.com India
474,744 Shares in ADC Therapeutics SA (NYSE:ADCT) Purchased by Affinity Asset Advisors LLC - MarketBeat
Affinity Asset Advisors LLC Makes New Investment in ADC Therapeutics SA (NYSE:ADCT) - Defense World
205,221 Shares in ADC Therapeutics SA (NYSE:ADCT) Purchased by Bank of New York Mellon Corp - MarketBeat
205,221 Shares in ADC Therapeutics SA (NYSE:ADCT) Bought by Bank of New York Mellon Corp - Defense World
Adc Therapeutics SA [ADCT] Investment Guide: What You Need to Know - Knox Daily
Acadian Asset Management LLC Invests $51,000 in ADC Therapeutics SA (NYSE:ADCT) - Defense World
Buying Buzz: Agree Realty Corp. [ADC] Director RAKOLTA JOHN JR purchases 20,000 shares of the company - Knox Daily
ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue - BioSpace
ADC Therapeutics SA (NYSE:ADCT) Short Interest Down 8.8% in August - Defense World
Short Interest in ADC Therapeutics SA (NYSE:ADCT) Declines By 8.8% - Defense World
Addus HomeCare (NASDAQ:ADUS) Reaches New 12-Month High at $136.12 - MarketBeat
ADC Therapeutics : Cantor Global Healthcare Conference Presentation - Marketscreener.com
Daily Progress: Agree Realty Corp. (ADC) Drop -0.96, Closing at 75.97 - The Dwinnex
ADC Therapeutics : Cantor Global Healthcare Conference 2024 Presentation - Marketscreener.com
Agree Realty (NYSE:ADC) Reaches New 52-Week High at $77.19 - MarketBeat
Quest Partners LLC Sells 20,070 Shares of Agree Realty Co. (NYSE:ADC) - MarketBeat
ADC Therapeutics (NYSE:ADCT) Trading 0.5% Higher - MarketBeat
Adc Therapeutics SA (ADCT) is a good investment, but the stock may be overvalued - US Post News
Insider’s View: Deciphering Adc Therapeutics SA (ADCT)’s Financial Health Through Ratios - The Dwinnex
ADCT (Adc Therapeutics SA) may reap gains as insiders became active recently - Knox Daily
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - Yahoo Finance UK
ADC Therapeutics to Present at Upcoming Investor Conferences - Yahoo Finance UK
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - GlobeNewswire
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - StockTitan
ADC Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire
ADC Therapeutics to Present at Upcoming Investor Conferences - Marketscreener.com
ADC Therapeutics to Present at Upcoming Investor Conferences - StockTitan
Adc Therapeutics SA (ADCT)’s stock performance: a year in review - US Post News
Are Smart Investors Making the Right Decision? Adc Therapeutics SA (ADCT) - SETE News
Adc Therapeutics SA (ADCT) rating initates by Cantor Fitzgerald - Knox Daily
Adc Therapeutics SA (ADCT) receives an Overweight rating from Cantor Fitzgerald - Knox Daily
ADC Therapeutics Insiders Forfeit On 10% Gains After Selling Stock - Simply Wall St
ADCT stock rated an Overweight by Cantor Fitzgerald - Knox Daily
Adcendo and Multitude ink ADC deal potentially worth $1bn - Pharmaceutical Technology
ADC Therapeutics SA (NYSE:ADCT) Sees Large Drop in Short Interest - Defense World
ADC Therapeutics SA (NYSE:ADCT) Sees Significant Decline in Short Interest - MarketBeat
Earnings call: ADC Therapeutics reports Q2 2024 financial results By Investing.com - Investing.com Australia
Earnings call: ADC Therapeutics reports Q2 2024 financial results By Investing.com - Investing.com Canada
Earnings call: ADC Therapeutics reports Q2 2024 financial results - Investing.com
Earnings call: ADC Therapeutics reports Q2 2024 financial results By Investing.com - Investing.com UK
ADC Therapeutics SA (NYSE:ADCT) Q2 2024 Earnings Call Transcript - Insider Monkey
Antibody Drug Conjugates Market to See Booming Growth 2024-2031 - openPR
ADC Therapeutics SA (ADCT) Q2 2024 Earnings Call Transcript - Seeking Alpha
FY2024 EPS Estimates for ADC Therapeutics SA Boosted by Analyst (NYSE:ADCT) - Defense World
ADC Therapeutics SA (NYSE:ADCT) to Post Q3 2024 Earnings of ($0.31) Per Share, Capital One Financial Forecasts - Defense World
ADC Therapeutics (NYSE:ADCT) Stock Rating Reaffirmed by Royal Bank of Canada - Defense World
ADC Therapeutics SA (NYSE:ADCT) Forecasted to Post FY2024 Earnings of ($2.04) Per Share - MarketBeat
HC Wainwright Reiterates Buy Rating for ADC Therapeutics (NYSE:ADCT) - MarketBeat
Adc Therapeutics Sa Stock (ADCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):